An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) arise from neuroendocrine cells found throughout the gastrointestinal tract and islet cells of the pancreas. The incidence and prevalence of GEP-NENs have been increasing each year due to higher awareness, improved diagnostic modalities, and increased incidental detection on cross-sectional imaging and endoscopy for cancer screening and other conditions and symptoms. GEP-NENs are a heterogeneous group of tumors and have a wide range in clinical presentation, histopathologic features, and molecular biology. Clinical presentation most commonly depends on whether the GEP-NEN secretes an active hormone. The World Health Organization recently updated the classification of GEP-NENs to introduce a distinction between high-grade neuroendocrine tumors and neuroendocrine carcinomas, which can be identified using histology and molecular studies and are more aggressive with a worse prognosis compared to high-grade neuroendocrine tumors. As our understanding of the biology of GEP-NENs has grown, new and improved diagnostic modalities can be developed and optimized. Here, we discuss clinical features and updates in diagnosis, including histopathological analysis, biomarkers, molecular techniques, and radiology of GEP-NENs. We review established diagnostic tests and discuss promising novel diagnostic tests that are currently in development or require further investigation and validation prior to broad utilization in patient care.

Automated summary

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are tumors that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. The incidence of GEP-NENs is increasing due to improved awareness and diagnostic techniques. GEP-NENs are a heterogeneous group of tumors, and their clinical presentation and molecular biology can vary greatly. The World Health Organization has recently updated the classification of GEP-NENs, introducing a distinction between high-grade neuroendocrine tumors and neuroendocrine carcinomas. This article discusses the clinical features and updates in the diagnosis of GEP-NENs, including histopathological analysis, biomarkers, molecular techniques, and radiology.